Coy Stull is a senior attorney in the firm’s Litigation Department and a member of its Intellectual Property Practice. His experience spans all stages of intellectual property litigation, including trial and appeals. Mr. Stull also has experience in preparation of opinions relating to infringement and validity.

Mr. Stull has represented both plaintiffs and defendants in federal courts, including matters before the International Trade Commission. He has litigated cases in a wide variety of technological areas including: industrial processes, nanomaterials, polymers, consumer products, pharmaceutical compositions, methods of drug delivery and treatment, chemical compounds, natural products and medical diagnostic devices. Mr. Stull’s practice includes experience in pharmaceutical litigation related to Abbreviated New Drug Applications (ANDA) created by the Hatch-Waxman Act. Mr. Stull also has experience with trademark and copyright disputes, including opposition and cancellation proceedings before the Trademark Trial and Appeal Board. Mr. Stull is a registered patent attorney and has experience in advising clients regarding IPRs and ex parte reexaminations.

Areas of Practice




Selected representations include:

  • Ceva Santé Animale and Horizon Valley Generics in a contract and Lanham Act litigation involving fipronil/methoprene veterinary products in the Middle District of Georgia.
  • West-Ward Pharmaceutical in Hatch-Waxman patent infringement litigation brought by Spectrum Pharmaceuticals in the District of Nevada involving patents concerning the drug product Fusilev® (levoleucovorin).
  • Teva Pharmaceuticals USA in Hatch-Waxman patent infringement litigation involving patents listed in the Orange Book and processes for SUBOXONE® (buprenorphine/naloxone sublingual film). Reckitt Benckiser et al v. Teva Pharmaceuticals USA.
  • Watson Laboratories and Andrx Labs in Hatch-Waxman patent infringement litigation involving patents listed in the Orange Book for OXYCONTIN® (extended-release oxycodone hydrochloride tablets). Case settled before trial. Purdue Pharma et al. v. Watson Laboratories et al. (S.D.N.Y.).
Professional Experience

Mr. Stull is a member of the American Intellectual Property Law Association (AIPLA) and the Federal Circuit Bar Association.

Prior to joining Goodwin in 2014, Mr. Stull was an associate in the Washington, D.C. office of Kenyon & Kenyon.

In The News







J.D., 2005
University of Miami School of Law

(cum laude)

B.S., Chemical Engineering, 2002
University of Florida
(with honors)



District of Columbia
U.S. Patent and Trademark Office (USPTO)


U.S. Supreme Court
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Middle District of Florida
U.S. District Court for the Southern District of Florida
Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers